6-month or 12-month adjuvant trastuzumab regimen for HER2-positive breast cancer? Decision-making in a resource-limited setting

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)e100
JournalThe Lancet Oncology
Volume23
Issue number3
DOIs
StatePublished - Mar 2022

Cite this